Reduced Chemotherapy in Low Risk DLBCL

Phase 4 Unknown 290 enrolled Ruijin Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a clinical trial to compare the efficacy and safety of four cycles of R-CHOP followed by four cycles of Rituximab with six cycles of R-CHOP followed by two cycles of Rituximab in the treatment of de novo, low-risk, non-bulky diffuse large B-cell lymphoma.

Timeline

Start: 2016-06-14
Primary completion: 2022-10-30
Completion: 2024-12-31

Publications

Shi Q, He Y, Yi HM, Mu RJ, Jiang XF, Fu D, Dong L, Qin W, Xu PP, Cheng S, Song Q, Chen SJ, Wang L, Zhao WL. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial. Cancer Commun (Lond). 2023 Aug;43(8):896-908. doi: 10.1002/cac2.12462. Epub 2023 Jul 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Subject	Epirubicin	Small molecule	70 mg/m2	Intravenous
Subject	Prednisone	Other / unclassified	60 mg/m2	Oral
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Subject	Vincristine	Small molecule	1.4 mg/m2	Intravenous

Reduced Chemotherapy in Low Risk DLBCL

Summary

Timeline

Publications

Drugs

Indications